Marksans Pharma arm Relonchem gets marketing authorization for Sennosides Tablets in UK
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-05-19 10:30 GMT | Update On 2025-05-19 10:30 GMT
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Sennosides 7.5 mg Tablets from UK Medicines & Healthcare Products Regulatory Agency.
Last week, Relonchem also received marketing authorization for Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Read also: After Baclofen, now Gabapentin: Marksans Pharma arm bags another UK MHRA green light
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.